DOCSLIB.ORG

Rs 000-000-260 AKT/Pkba Substrate 1.0 Mg/Ml 500 Μ

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rs 000-000-260 AKT/Pkba Substrate 1.0 Mg/Ml 500 Μ Catalog Number Display Name Concentration ValueSize Default Unit List price - Rs 000-000-260 AKT/PKBa Substrate 1.0 mg/mL 500 µg 24,434.00 000-000-264 NFKB p65 (Rel A) pS276 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-264NP NFKB p65 (Rel A) S276 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-266 p65 (Rel A) pS529 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-266NP p65 (Rel A) S529 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-383 DYKDDDDK (FLAG®) Peptide 1 mg/mL 1.0 mg 12,285.00 000-000-398 ATM S1981 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-400 ATM pS1981 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-401 AKT Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-402 Angiopoietin 2 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-403 Angiopoietin 1 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-404 Osteopontin Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-405 NOTCH 1 (intra) (Human specific) Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-407 NOTCH 1 (Human specific) Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-408 NOTCH 2 (Human specific) Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-410 ASK-1 phospho specific pS83 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-410NP ASK-1 non phospho specific S83 Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-433 Huntington pS421 Control Phospho Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-450 Huntington S421 Control Non-Phospho Peptide 1.0 mg/mL 50 µg 13,787.00 000-000-H47 Triple FLAG® Peptide 1.0 mg/ml 1.0 mg 12,285.00 000-000-K95 Beta Amyloid 40, Peptide 1.0 mg/mL 1.0 mg 1,06,334.00 000-000-K95S Beta Amyloid 40, Peptide 1.0 mg/mL 0.5 mg 27,164.00 000-000-M33 LL-37, Rhodamine conjugated 1.0 mg/mL 1 mg 52,553.00 000-001-200 Glutathione-S-Transferase (GST) Control Protein 0.99 mg/mL 100 µg 16,790.00 000-001-215 Green Fluorescent Protein (GFP) Control Protein 1.0 mg/mL 100 µg 42,179.00 000-001-271 NFKB p65 NLS specific Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-282 p33 ING1 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-283 p47 ING3 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-284 p29 ING4 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-285 p28 ING5 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-287 AP2A Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-288 IDN3 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-289 Human AP1G1 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-290 AP3D1 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-342 UBC13 Peptide 1.0 mg/mL 50 µg 13,787.00 Recombinant Red Fluorescent Protein (RFP) 000-001-379 Control 1.0 mg/mL 100 µg 42,179.00 000-001-385-1 Maltose Binding Protein (MBP) Control Protein 1.0 mg/mL 1 mg 19,383.00 000-001-385-5 Maltose Binding Protein (MBP) Control Protein 5.0 mg/mL 5 mg 46,274.00 000-001-391 HR23B Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-453 Human MDC1 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-461 MAD2L1 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-470 MAD2L2 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-482 HAUSP Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-483 ßTrCP2 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-485 F-Box Protein 43 (Fbp5B) Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-486 Btb1 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-487 Apg7 Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-490 F-Box Protein Fbp5A Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-498 Hus1B Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-B98 DbpA Control Protein 1.0mg/mL 100 µg 42,998.00 000-001-C09 Erpd/Arp37 Control Protein 1.0mg/mL 100 µg 42,998.00 000-001-C10 ErpN/OspE Control Protein 1.0 mg/mL 100 µg 42,998.00 000-001-C11 OspC Control Protein 1.0 mg/mL 100 µg 42,998.00 000-001-C12 p35 Control Protein 1.0mg/mL 100 µg 42,998.00 000-001-C13 OspA Control Protein 1.04 mg/mL 100 µg 42,998.00 000-001-C14 Flagellin Control Protein 1.0mg/mL 100 µg 42,998.00 000-001-C15 OspB Control Protein 1.0 mg/mL 100 µg 42,998.00 000-001-C16 DbpB Control Protein 1.0mg/mL 100 µg 42,998.00 000-001-C17 p39 Control Protein 1.0 mg/mL 100 µg 42,998.00 000-001-C18 Crasp1 Control Protein 1.0 mg/mL 100 µg 42,998.00 000-001-C19 Crasp2 Control Protein 1.0 mg/mL 100 µg 42,998.00 000-001-C30 Surface Lipoprotein p27 Control Protein 1.0mg/mL 100 µg 42,998.00 000-001-C33 VlsE Control Protein 1.0mg/mL 100 µg 42,998.00 000-001-E71 AKT2 Control Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-J08 E.coli HCP Control 2 mg/ml 50 µg 15,288.00 000-001-J35 AKT2 Control Peptide 1.0 mg/mL 50 µg 13,787.00 000-001-K14 Histone H3, 21-44 K27Me 1.0 mg/mL 1 mg 27,164.00 000-001-K15 H321-44K27me1 1.0 mg/mL 1 mg 35,354.00 000-001-K16 H321-44K27me2 1.0 mg/mL 1 mg 31,259.00 000-001-K17 H321-44K27me3 1.0 mg/mL 1 mg 33,443.00 000-001-K18 Histone H3, 21-44 1.0 mg/mL 1 mg 27,164.00 000-001-K19 Histone H3, 21-40 1.0 mg/mL 1 mg 27,164.00 000-001-K20 Histone H3, 21-35 1.0 mg/mL 1 mg 24,434.00 000-001-K21 Histone H3, 23-35 1.0 mg/mL 1 mg 24,434.00 000-001-K38 H31-21K4Me2 1.0 mg/mL 1 mg 31,259.00 000-001-K41 H31-16K4Me3 1.0 mg/mL 1 mg 27,164.00 000-001-K42 Histone H4, 36-50 1.0 mg/mL 1 mg 23,069.00 000-001-K43 Histone H4, 36-50 K44Me3 1.0 mg/mL 1 mg 24,980.00 000-001-K44 Histone H4, 36-50 K44Me1 1.0 mg/mL 1 mg 27,983.00 000-001-K45 Histone H4, 36-50 K44Me2 1.0 mg/mL 1 mg 24,980.00 000-001-K46 Histone H3, 1-21 K4Me3 1.0 mg/mL 1 mg 39,449.00 000-001-K47 Histone H3, 26-46 1.0 mg/mL 1 mg 27,164.00 000-001-K48 H3, 1-18, K4Me2/K9Ac/K14Ac 1.0 mg/mL 1 mg 33,989.00 000-001-K49 Histone H3, 1-18 K4Me3/K9/K14ac 1.0 mg/mL 1 mg 39,449.00 000-001-K94 Beta Amyloid 40 Peptide 1 mg/mL 1 mg 23,069.00 000-001-K97 Beta Amyloid 40, Dutch Mutant 1.0 mg/mL 1 mg 47,093.00 000-001-K98 Beta Amyloid 40, Arctic Mutant Peptide 1.0 mg/mL 1 mg 47,093.00 000-001-K99 Beta Amyloid 40, Italian Mutant 1.0 mg/mL 1 mg 47,093.00 000-001-L00 Beta Amyloid 16 1.0 mg/mL 1 mg 8,463.00 000-001-L01 Beta Amyloid 42 Peptide 1.0 mg/mL 1 mg 33,989.00 000-001-L02 Beta Amyloid 42, Dutch Mutant Peptide 1.0 mg/mL 1 mg 57,194.00 000-001-L03 Beta Amyloid 42, Iowa Mutant Peptide 1.0 mg/mL 1 mg 57,194.00 000-001-L04 Beta Amyloid 42, Flemish Mutant Peptide 1.0 mg/mL 1 mg 57,194.00 000-001-L05 Beta Amyloid 42, Italian Mutant 1.0 mg/mL 1 mg 57,194.00 000-001-L06 Beta Amyloid 25-35 Peptide 1.0 mg/mL 1 mg 7,917.00 000-001-L07 Beta Amyloid 25-35 Peptide 1.0 mg/mL 1 mg 7,917.00 000-001-L08 Beta Amyloid 25-35 Peptide 1.0 mg/mL 1 mg 9,282.00 000-001-L09 Beta Amyloid 25-35 1 mg/mL 1 mg 9,282.00 000-001-L10 Beta Amyloid 3-11 Peptide 1.0 mg/mL 1 mg 8,463.00 000-001-L11 Beta Amyloid 3-11 Peptide 1.0 mg/mL 1 mg 8,463.00 000-001-L12 Beta Amyloid pyrE 3-11 1.0 mg/mL 1 mg 11,330.00 000-001-L13 Beta Amyloid pyrE 3-11 Peptide 1.0 mg/mL 1 mg 11,330.00 000-001-L14 Beta Amyloid pyrE 11-19 1.0 mg/mL 1 mg 8,463.00 000-001-L15 Beta Amyloid pyrE 3-40 Peptide 1.0 mg/mL 1 mg 33,989.00 000-001-L16 Beta Amyloid pyrE 11-40 Peptide 1.0 mg/mL 1 mg 36,719.00 000-001-L17 Beta Amyloid 3-40 Peptide 1.0 mg/mL 1 mg 39,449.00 000-001-L18 Beta Amyloid 11-40 1.0 mg/mL 1 mg 36,719.00 000-001-L19 Beta Amyloid pyrE 3-42 Peptide 1.0 mg/mL 1 mg 44,909.00 000-001-L20 Beta Amyloid pyrE 11-42 Peptide 1.0 mg/mL 1 mg 33,989.00 000-001-L21 Beta Amyloid 3-42 Peptide 1.0 mg/mL 1 mg 41,633.00 000-001-L22 Beta Amyloid 11-42 Peptide 1.0 mg/mL 1 mg 26,345.00 000-001-L23 CEFT panel 23 peptides 1.0 mg/mL 1 Pack 2,38,739.00 000-001-L24 CEFT panel 32 peptides 1.0 mg/mL 1 mg 2,83,238.00 000-001-L56 Apelin 36, human 1.0 mg/mL 1 mg 36,719.00 000-001-L56L Apelin 36, human 1.0 mg/mL 5 mg 1,48,649.00 000-001-L57 Apelin,17, human, bovine, rat, mouse 1.0 mg/mL 1 mg 12,695.00 000-001-L57L Apelin,17, human, bovine, rat, mouse 1.0 mg/mL 5 mg 51,734.00 000-001-L58 Apelin 13, pyr1, human, bovine, rat, mouse 1.0 mg/mL 1 mg 9,828.00 000-001-L58L Apelin 13, pyr1, human, bovine, rat, mouse 1.0 mg/mL 5 mg 39,449.00 000-001-L59 Apelin 12, human, bovine, rat, mouse 1 mg/mL 1 mg 9,282.00 000-001-L59L Apelin 12, human, bovine, rat, mouse 1.0 mg/mL 5 mg 36,719.00 000-001-L60 Apelin 13, pyr1, [13C/15N-Pro3, 12] 1.0 mg/mL 1 mg 1,48,103.00 000-001-L60S Apelin 13, pyr1, [13C/15N-Pro3, 12] 1.0 mg/mL 0.1 mg 49,823.00 000-001-L61 Apelin 13, pyr1, dSer6, [13C/15N-Pro3, 12] 1.0 mg/mL 1 mg 1,48,103.00 000-001-L61S Apelin 13, pyr1, dSer6, [13C/15N-Pro3, 12] 1.0 mg/mL 0.1 mg 49,823.00 000-001-L62 Apelin 13, pyr1, dLeu5, [13C/15N-Pro3, 12] 1.0 mg/mL 1 mg 1,48,103.00 000-001-L62S Apelin 13, pyr1, dLeu5, [13C/15N-Pro3, 12] 1.0 mg/mL 0.1 mg 49,823.00 000-001-L63 Apelin 12, N-α-MCA, C-α-DAP(DNP) 1.0 mg/mL 1 mg 44,909.00 000-001-L63L Apelin 12, N-α-MCA, C-α-DAP(DNP) 1.0 mg/mL 5 mg 1,80,863.00 000-001-L64 Apelin 12, N-α-MCA, Control 1.0 mg/mL 1 mg 19,520.00 000-001-L64L Apelin 12, N-α-MCA, Control 1.0 mg/mL 5 mg 74,393.00 000-001-L65 N-α-palmitoyl-apelin 13 1.0 mg/mL 1 mg 22,250.00 000-001-L65L N-α-palmitoyl-apelin 13 1.0 mg/mL 5 mg 88,589.00 000-001-L66 N-α-lauroyl-apelin 13 1.0 mg/mL 1 mg 22,250.00 000-001-L66L N-α-lauroyl-apelin 13 1.0 mg/mL 5 mg 88,589.00 000-001-L67 N-α-myristoyl-apelin 13 1.0 mg/mL 1 mg 22,250.00 000-001-L67L N-α-myristoyl-apelin 13 1.0 mg/mL 5 mg 88,589.00 000-001-L68 N-α-stearoyl-apelin 13 1.0 mg/mL 1 mg 22,250.00 000-001-L68L N-α-stearoyl-apelin 13 1.0 mg/mL 5 mg 88,589.00 000-001-L69 Apelin 13, pyr1, Glu2 1.0 mg/mL 1 mg 9,828.00 000-001-L69L Apelin 13, pyr1, Glu2 1.0 mg/mL 5 mg 39,449.00 000-001-L70 Apelin 13, pyr1, Lys7 1.0 mg/mL 1 mg 9,828.00 000-001-L70L Apelin 13, pyr1, Lys7 1.0 mg/mL 5 mg 39,449.00 000-001-L71 Apelin 13, pyr1, Ile12 1.0 mg/mL 1 mg 9,828.00 000-001-L71L Apelin 13, pyr1, Ile12 1.0 mg/mL 5 mg 39,449.00 000-001-L72 Apelin 13, pyr1, Asn11 1.0 mg/mL 1 mg 9,828.00 000-001-L72L Apelin 13, pyr1, Asn11 1.0 mg/mL 5 mg 39,449.00 000-001-L73 Apelin 13, pyr1, Cys11 1.0 mg/mL 1 mg 9,828.00 000-001-L73L Apelin 13, pyr1, Cys11 1.0 mg/mL 5 mg 39,449.00 000-001-L74 Apelin 13, pyr1, Phe11 1.0 mg/mL 1 mg 9,828.00
Load more

Recommended publications
  • Additional Methods
    Additional Methods Cell Expression Profiles The tissue-dependent gene expression dataset from the Genome Novartis Foundation contains 32 healthy major tissues, and 47 tumour samples and cell lines. The custom- designed whole-genome gene expression microarrays used on each sample targets 44775 human mRNA transcripts. Previous analysis of this dataset identified many chromo- somal regions of correlated transcription that are under the control of both tissue and parental allele-specific expression. The expression levels of TF genes across tissue sam- ples are observed to be lower than non-TF genes. This is coherent with the mechanistic explanation that the effect of a single TF molecule is amplified by transcribing many copies of mRNA from a target gene. Across all samples, the proportion of TFs rel- ative to all expressed genes is remarkably stable at ∼ 6%. In the bootstrap test for highly predictive CRMs, we resampled from this set of TFs to generate the bootstrap replicates. High variance in gene expression profiles are observed between replicates for samples with more heterogeneous composition. Therefore, we treat each replicate as an independent sample in our analysis. When analyzing expression variation in a single sample, we found that a Gaussian distributional assumption for gene expression is more suitable compared to other distributions. Smoothing and Model Fitting Since gene expression response by the target gene varies over different TF expression values in a smooth fashion, a curved function is needed to fit our gene expression data. For additive models, the partial response of the target gene to the expression of each TF is described by a smooth function.
    [Show full text]
  • Alpha Actinin 4: an Intergral Component of Transcriptional
    ALPHA ACTININ 4: AN INTERGRAL COMPONENT OF TRANSCRIPTIONAL PROGRAM REGULATED BY NUCLEAR HORMONE RECEPTORS By SIMRAN KHURANA Submitted in partial fulfillment of the requirements for the degree of doctor of philosophy Thesis Advisor: Dr. Hung-Ying Kao Department of Biochemistry CASE WESTERN RESERVE UNIVERSITY August, 2011 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of SIMRAN KHURANA ______________________________________________________ PhD candidate for the ________________________________degree *. Dr. David Samols (signed)_______________________________________________ (chair of the committee) Dr. Hung-Ying Kao ________________________________________________ Dr. Edward Stavnezer ________________________________________________ Dr. Leslie Bruggeman ________________________________________________ Dr. Colleen Croniger ________________________________________________ ________________________________________________ May 2011 (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. TABLE OF CONTENTS LIST OF TABLES vii LIST OF FIGURES viii ACKNOWLEDEMENTS xii LIST OF ABBREVIATIONS xiii ABSTRACT 1 CHAPTER 1: INTRODUCTION Family of Nuclear Receptors 3 Mechanism of transcriptional regulation by co-repressors and co-activators 8 Importance of LXXLL motif of co-activators in NR mediated transcription 12 Cyclic recruitment of co-regulators on the target promoters 15 Actin and actin related proteins (ABPs) in transcription
    [Show full text]
  • Mouse Anti-Human Testicular Receptor 4
    Catalog Clonality, clone Reactive Reg. Product Name Quantity Applications Number (isotype) species Status mAb clone H0107B WB, ELISA, 434700 Mouse anti-human TR4 100 µg Hu, Ms, Rt RUO (Ms IgG2a) IP, IHC Mouse Anti-Human Testicular Receptor 4 Description Testicular receptor 4 (TR4, TAK1; NR2C2) is a member of the orphan nuclear receptor family. TR4 was originally cloned from lymphoblastoma Raji cells or mouse brain cDNA library. No ligand has been reported. Northern blot shows TR4 is transcribed as a 9kb mRNA in many tissues and as a 2.8kb mRNA in testis, mainly in spermatocytes. TR4 has two isoforms called TR4α1 and TR4-α2, which differ in 19 amino acids coded by two separate exons. Both products translated from 9kb transcript are ubiquitously expressed. Since TR4 binds to the same elements for the RAR-RXR or TR-RXR heterodimers, TR4 may have an inhibitory affect for retinoic-acid mediated transactivation. Nomenclature NR2C2 Genbank L27586 Origin Produced in BALB/c mouse ascites after inoculation with hybridoma of mouse myeloma cells (NS-1) and spleen cells derived from a BALB/c mouse immunized with Baculovirus-expressed recombinant human TR4 (23-52 aa). Specificity This antibody specifically recognizes human TR4 and cross reacts with mouse and rat TR4. Purification Ammonium sulfate fractionation Formulation Concentration is 1 mg/mL in physiological saline with 0.1% sodium azide as a preservative. Application Recommended Concentration* Western Blot 2 μg/mL Non reducing Western Blot Not tested ELISA 0.1 μg/mL Immunoprecipitation Determine by use Electrophoretic Mobility Shift Assay Not tested Chromatin Immunoprecipitation Not tested Immunohistochemistry 10 μg/mL *In order to obtain the best results, optimal working dilutions should be determined by each individual user.
    [Show full text]
  • Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases
    Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Olivares, Ana Maria, Oscar Andrés Moreno-Ramos, and Neena B. Haider. 2015. “Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases.” Journal of Experimental Neuroscience 9 (Suppl 2): 93-121. doi:10.4137/JEN.S25480. http:// dx.doi.org/10.4137/JEN.S25480. Published Version doi:10.4137/JEN.S25480 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320246 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Journal name: Journal of Experimental Neuroscience Journal type: Review Year: 2015 Volume: 9(S2) Role of Nuclear Receptors in Central Nervous System Running head verso: Olivares et al Development and Associated Diseases Running head recto: Nuclear receptors development and associated diseases Supplementary Issue: Molecular and Cellular Mechanisms of Neurodegeneration Ana Maria Olivares1, Oscar Andrés Moreno-Ramos2 and Neena B. Haider1 1Department of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA. 2Departamento de Ciencias Biológicas, Facultad de Ciencias, Universidad de los Andes, Bogotá, Colombia. ABSTRACT: The nuclear hormone receptor (NHR) superfamily is composed of a wide range of receptors involved in a myriad of important biological processes, including development, growth, metabolism, and maintenance.
    [Show full text]
  • Full-Text PDF (Final Published Version)
    Alexander, S. P. H., Cidlowski, J. A., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors. British Journal of Pharmacology, 174, S208-S224. https://doi.org/10.1111/bph.13880 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13880 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13880 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Nuclear hormone receptors. British Journal of Pharmacology (2017) 174, S208–S224 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors Stephen PH Alexander1, John A Cidlowski2, Eamonn Kelly3, Neil V Marrion3, John A Peters4, Elena Faccenda5, Simon D Harding5,AdamJPawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical
    [Show full text]
  • Anti-Testicular Receptor 2 (TR2) (Rabbit) Antibody - 100-401-E45
    Anti-Testicular Receptor 2 (TR2) (Rabbit) Antibody - 100-401-E45 Code: 100-401-E45 Size: 100 µL Product Description: Anti-Testicular Receptor 2 (TR2) (Rabbit) Antibody - 100-401-E45 Concentration: Titrated value sufficient to run approximately 10 mini blots. PhysicalState: Liquid Label Unconjugated Host Rabbit Gene Name NR2C1 Species Reactivity mouse, human, rat Storage Condition Store vial at -20° C prior to opening. This product is stable at 4° C as an undiluted liquid. For extended storage, aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Dilute only prior to immediate use. Synonyms Nuclear receptor subfamily 2 group C member 1, Orphan nuclear receptor TR2, mTR2 Application Note Anti-Testicular Receptor 2 (Rabbit) antibody is suitable for use in Western Blots. Anti-Testicular Receptor 2 antibodies are specific for the ~64 kDa TR2 protein in Western blots of testes and nuclear extracts from MEL cell lines. Researchers should determine optimal titers for applications that are not stated below. Background TR2 antibody detects Testicular receptor 2 (TR2), which is a member of the orphan nuclear receptor family. It is widely expressed at a low level throughout the adult testis. TR2 represses transcription and binds DNA directly interacting with HDAC3 and HDAC4 via DNA-binding domains. TR2 has also been implicated in regulation of estrogen receptor activity in mammary glands. In addition, TR2 has recently been shown to form a heterodimer with TR4 that can bind to the direct repeat 6 element of the hepatitis B virus (HBV) enhancer II region thus suppressing HBV gene expression.
    [Show full text]
  • Characterization of Transcription Factor Complexes Involved in Globin Gene Regulation
    Characterization of Transcription Factor Complexes involved in Globin Gene Regulation Katarzyna Ewa Kołodziej 26th March 2008 Cover: Rodota The work presented in this thesis was performed at the Department of Cell Biology at the Erasmus Univer- sity Medical Center Rotterdam. This department is member of the Medisch Genetisch Centrum Zuid-West Nederland. The research was partially supported by the Netherlandse Organizatie voor Wetenschappelijk Onderzoek (NWO) and by EU. Characterization of Transcription Factor Complexes involved in Globin Gene Regulation Karakterizering van transcriptie factor complexen betrokken bij de regulatie van globine genen PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de Rector Magnificus Prof.dr. S.W.J. Lamberts en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 26 maart 2008 om 15.45 uur. door Katarzyna Ewa Kołodziej geboren te Wrocław, Polen Promotiecommissie Promotor: Prof.dr. F.G. Grosveld Overige laden: Prof.dr. J.N.J. Philipsen Prof.dr. J.D. Engel Dr.ir. D.N. Meijer Copromotor: Dr. J. Strouboulis Moim rodzicom & for Luc TABLE OF CONTENTS Chapter 1 : Introduction 9 Chapter 2 : Isolation of transcription factor complexes by in vivo biotinylation tagging and direct binding to streptavidin beads (Patrick Rodriguez, Harald Braun, Katarzyna E. Kolodziej, Ernie de Boer, Jennifer Campbel, Edgar Bonte, Sjaak Philipsen and John Strouboulis Methods Mol Bio. 2006; 338: 305-23 ) 33 Chapter 3 : GATA-1 forms distinct activating and repressive complexes in erythroid cells (Patrick Rodriguez, Edgar Bonte, Jeroen Krijgsveld, Katarzyna E. Kolodziej, Boris Guyot, Albert Heck, Paresh Vyas, Ernie de Boer, Frank Grosveld and John Strouboulis, EMBO J.
    [Show full text]
  • Recent Advances in Understanding Corticotroph Pituitary Tumor Initiation and Progression [Version 1; Peer Review: 2 Approved] Ulrich Renner , Denis Ciato , Günter K
    F1000Research 2018, 7(F1000 Faculty Rev):1354 Last updated: 17 JUL 2019 REVIEW Recent advances in understanding corticotroph pituitary tumor initiation and progression [version 1; peer review: 2 approved] Ulrich Renner , Denis Ciato , Günter K. Stalla Max Planck Institute of Psychiatry, Clinical Neuroendocrinology Group, Munich, Germany First published: 29 Aug 2018, 7(F1000 Faculty Rev):1354 ( Open Peer Review v1 https://doi.org/10.12688/f1000research.14789.1) Latest published: 29 Aug 2018, 7(F1000 Faculty Rev):1354 ( https://doi.org/10.12688/f1000research.14789.1) Reviewer Status Abstract Invited Reviewers Cushing’s disease is the most frequent form of hypercortisolism and is 1 2 caused by hypophyseal corticotroph adenomas secreting excessive amounts of adrenocorticotropic hormone. Most of the tumors develop version 1 sporadically and only a limited number of corticotroph adenomas have published been found to be associated with different neuroendocrine syndromes or 29 Aug 2018 with familial isolated pituitary adenomas. The pathogenic mechanisms of corticotroph adenomas are largely unknown, but the discovered aberrant chaperoning activity of heat shock protein 90 on the one hand and the F1000 Faculty Reviews are written by members of presence of ubiquitin-specific protease 8 mutations on the other hand the prestigious F1000 Faculty. They are partially explained the causes of their development. Corticotroph tumors commissioned and are peer reviewed before arise initially as benign microadenomas but with time form invasively publication to ensure that the final, published version growing aggressive macroadenomas which can switch to corticotroph carcinomas in extremely rare cases. The mechanisms through which is comprehensive and accessible. The reviewers corticotroph tumors escape from glucocorticoid negative feedback are still who approved the final version are listed with their poorly understood, as are the processes that trigger the progression of names and affiliations.
    [Show full text]
  • Alternative Splicing in the Nuclear Receptor Superfamily Expands Gene Function to Refine Endo-Xenobiotic Metabolism S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2020/01/24/dmd.119.089102.DC1 1521-009X/48/4/272–287$35.00 https://doi.org/10.1124/dmd.119.089102 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 48:272–287, April 2020 Copyright ª 2020 by The American Society for Pharmacology and Experimental Therapeutics Minireview Alternative Splicing in the Nuclear Receptor Superfamily Expands Gene Function to Refine Endo-Xenobiotic Metabolism s Andrew J. Annalora, Craig B. Marcus, and Patrick L. Iversen Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon (A.J.A., C.B.M., P.L.I.) and United States Army Research Institute for Infectious Disease, Frederick, Maryland (P.L.I.) Received August 16, 2019; accepted December 31, 2019 ABSTRACT Downloaded from The human genome encodes 48 nuclear receptor (NR) genes, whose Exon inclusion options are differentially distributed across NR translated products transform chemical signals from endo- subfamilies, suggesting group-specific conservation of resilient func- xenobiotics into pleotropic RNA transcriptional profiles that refine tionalities. A deeper understanding of this transcriptional plasticity drug metabolism. This review describes the remarkable diversifica- expands our understanding of how chemical signals are refined and tion of the 48 human NR genes, which are potentially processed into mediated by NR genes. This expanded view of the NR transcriptome over 1000 distinct mRNA transcripts by alternative splicing (AS). The informs new models of chemical toxicity, disease diagnostics, and dmd.aspetjournals.org average human NR expresses ∼21 transcripts per gene and is precision-based approaches to personalized medicine.
    [Show full text]
  • MAGE-A11 Is Activated Through TFCP2/ZEB1 Binding Sites De-Methylation As Well As Histone Modification and Facilitates ESCC Tumor Growth
    www.impactjournals.com/oncotarget/ Oncotarget, 2018, Vol. 9, (No. 3), pp: 3365-3378 Research Paper MAGE-A11 is activated through TFCP2/ZEB1 binding sites de-methylation as well as histone modification and facilitates ESCC tumor growth Shina Liu1,*, Fei Liu1,*, Weina Huang1, Lina Gu1, Lingjiao Meng1, Yingchao Ju1,2, Yunyan Wu1, Juan Li1, Lihua Liu1 and Meixiang Sang1,3 1Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, P. R. China 2Animal Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, P. R. China 3Tumor Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, P. R. China *These authors contributed equally to this work Correspondence to: Meixiang Sang, email: [email protected] Keywords: MAGE-A11; ESCC; DNA methylation; histone acetylation; histone methylation Received: September 30, 2017 Accepted: November 15, 2017 Published: December 05, 2017 Copyright: Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Recently, we have reported that the product of Melanoma Antigens Genes (MAGE) family member MAGE-A11 is an independent poor prognostic marker for esophageal squamous cell carcinoma (ESCC). However, the reason how MAGE-A11 is activated in ESCC progression still remains unclear. In the current study, we demonstrated that DNA methylation and the subsequent histone posttranslational modifications play crucial roles in the regulation of MAGE-A11 in ESCC progression. We found that the methylation rate of TFCP2/ZEB1 binding site on MAGE-A11 promoter in ESCC tissues and cells is higher than the normal esophageal epithelial tissues and cells.
    [Show full text]
  • Molecular Signatures Differentiate Immune States in Type 1 Diabetes Families
    Page 1 of 65 Diabetes Molecular signatures differentiate immune states in Type 1 diabetes families Yi-Guang Chen1, Susanne M. Cabrera1, Shuang Jia1, Mary L. Kaldunski1, Joanna Kramer1, Sami Cheong2, Rhonda Geoffrey1, Mark F. Roethle1, Jeffrey E. Woodliff3, Carla J. Greenbaum4, Xujing Wang5, and Martin J. Hessner1 1The Max McGee National Research Center for Juvenile Diabetes, Children's Research Institute of Children's Hospital of Wisconsin, and Department of Pediatrics at the Medical College of Wisconsin Milwaukee, WI 53226, USA. 2The Department of Mathematical Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA. 3Flow Cytometry & Cell Separation Facility, Bindley Bioscience Center, Purdue University, West Lafayette, IN 47907, USA. 4Diabetes Research Program, Benaroya Research Institute, Seattle, WA, 98101, USA. 5Systems Biology Center, the National Heart, Lung, and Blood Institute, the National Institutes of Health, Bethesda, MD 20824, USA. Corresponding author: Martin J. Hessner, Ph.D., The Department of Pediatrics, The Medical College of Wisconsin, Milwaukee, WI 53226, USA Tel: 011-1-414-955-4496; Fax: 011-1-414-955-6663; E-mail: [email protected]. Running title: Innate Inflammation in T1D Families Word count: 3999 Number of Tables: 1 Number of Figures: 7 1 For Peer Review Only Diabetes Publish Ahead of Print, published online April 23, 2014 Diabetes Page 2 of 65 ABSTRACT Mechanisms associated with Type 1 diabetes (T1D) development remain incompletely defined. Employing a sensitive array-based bioassay where patient plasma is used to induce transcriptional responses in healthy leukocytes, we previously reported disease-specific, partially IL-1 dependent, signatures associated with pre and recent onset (RO) T1D relative to unrelated healthy controls (uHC).
    [Show full text]
  • WO 2019/089982 Al 09 May 2019 (09.05.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/089982 Al 09 May 2019 (09.05.2019) W 1P O PCT (51) International Patent Classification: (71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400 C12Q 1/6897 (2018.01) CI2N 15/65 (2006.01) Dexter Avenue N, Suite 1200, Seattle, Washington 98109 C12Q 1/02 (2006.01) G01N 33/50 (2006.01) (US). C12N 5/0783 (2010.01) (72) Inventors: AMIN, Rupesh; 400 Dexter Avenue N., Suite (21) International Application Number: 1200, Seattle, Washington 98109 (US). CHEN, Aye; 400 PCT/US20 18/058781 Dexter Avenue N., Suite 1200, Seattle, Washington 98109 (US). (22) International Filing Date: 0 1 November 2018 (01. 11.2018) (74) Agent: AHN, Sejin et al.; Morrison & Foerster LLP, 1253 1 High Bluff Drive, Suite 100, San Diego, California (25) Filing Language: English 92130-2040 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/580,405 0 1 November 2017 (01. 11.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/596,758 08 December 2017 (08. 12.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/599,672 15 December 2017 (15. 12.2017) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: METHOD OF ASSESSING ACTIVITY OF RECOMBINANT ANTIGEN RECEPTORS FIG.
    [Show full text]